These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 39337526)

  • 1. The Role of Microbial Metabolites in the Progression of Neurodegenerative Diseases-Therapeutic Approaches: A Comprehensive Review.
    Missiego-Beltrán J; Beltrán-Velasco AI
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review.
    Mincic AM; Antal M; Filip L; Miere D
    Clin Nutr; 2024 Jul; 43(7):1832-1849. PubMed ID: 38878554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut microbiome: an important role in neurodegenerative diseases and their therapeutic advances.
    Li S; Zhao L; Xiao J; Guo Y; Fu R; Zhang Y; Xu S
    Mol Cell Biochem; 2024 Sep; 479(9):2217-2243. PubMed ID: 37787835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbial Metabolome and Dysbiosis in Neurodegenerative Diseases: Psychobiotics and Fecal Microbiota Transplantation as a Therapeutic Approach-A Comprehensive Narrative Review.
    Uceda S; Echeverry-Alzate V; Reiriz-Rojas M; Martínez-Miguel E; Pérez-Curiel A; Gómez-Senent S; Beltrán-Velasco AI
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health.
    Parker A; Fonseca S; Carding SR
    Gut Microbes; 2020; 11(2):135-157. PubMed ID: 31368397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the microbial map and its implications in the therapeutics of neurodegenerative disorder.
    Vashishth S; Ambasta RK; Kumar P
    Ageing Res Rev; 2024 Sep; 100():102466. PubMed ID: 39197710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
    Wu J; Yang K; Fan H; Wei M; Xiong Q
    Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota dysbiosis and its impact on asthma and other lung diseases: potential therapeutic approaches.
    Kim YC; Sohn KH; Kang HR
    Korean J Intern Med; 2024 Sep; 39(5):746-758. PubMed ID: 39252487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain modulation by the gut microbiota: From disease to therapy.
    Mitra S; Dash R; Nishan AA; Habiba SU; Moon IS
    J Adv Res; 2023 Nov; 53():153-173. PubMed ID: 36496175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential treatment target.
    Olejnik P; Buczma K; Cudnoch-Jędrzejewska A; Kasarełło K
    Immunol Res; 2024 Aug; 72(4):554-565. PubMed ID: 38446328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus.
    Du L; Li Q; Yi H; Kuang T; Tang Y; Fan G
    Biomed Pharmacother; 2022 May; 149():112839. PubMed ID: 35325852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases.
    Loh JS; Mak WQ; Tan LKS; Ng CX; Chan HH; Yeow SH; Foo JB; Ong YS; How CW; Khaw KY
    Signal Transduct Target Ther; 2024 Feb; 9(1):37. PubMed ID: 38360862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiomes in physiology: insights into 21st-century global medical challenges.
    Shehata E; Parker A; Suzuki T; Swann JR; Suez J; Kroon PA; Day-Walsh P
    Exp Physiol; 2022 Apr; 107(4):257-264. PubMed ID: 35081663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases.
    Di Meo F; Donato S; Di Pardo A; Maglione V; Filosa S; Crispi S
    Curr Drug Metab; 2018; 19(6):478-489. PubMed ID: 29623833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
    Huda MN; Kim M; Bennett BJ
    Front Endocrinol (Lausanne); 2021; 12():632335. PubMed ID: 33897618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review on the pharmacological role of gut microbiome in neurodegenerative disorders: potential therapeutic targets.
    Aziz N; Wal P; Patel A; Prajapati H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; 397(10):7307-7336. PubMed ID: 38734839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.
    Westfall S; Lomis N; Kahouli I; Dia SY; Singh SP; Prakash S
    Cell Mol Life Sci; 2017 Oct; 74(20):3769-3787. PubMed ID: 28643167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.
    Zhu T; Goodarzi MO
    Curr Nutr Rep; 2020 Jun; 9(2):83-93. PubMed ID: 32157661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.
    Cuevas-Sierra A; Ramos-Lopez O; Riezu-Boj JI; Milagro FI; Martinez JA
    Adv Nutr; 2019 Jan; 10(suppl_1):S17-S30. PubMed ID: 30721960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.